Get started

Pharmastocks

CIPLA - Rising Wedge/Bear Flag - Intraday/Short TermThis analysis is purely based on price action and Chart Patterns. The analysis is on 15min TF hence target can be achieved in intraday trade or in couple of days Trade strategy is explained in image itself. Don't run after the price. Always plan your trade & trade your plan Keep trailing SL accordingly once entered into the trade. Trade at your own risk and money management. Do your own study before taking any trade Feel free to comment for any queries & suggestion
NSE:CIPLAShort
by AdityaKarn90
1
WAVE.V -- Bottoming Out Undervalued Pharma/COVID-19 PlayThe most attractive part of WAVE.V is share structure: 54M total float with 41M shares held by insiders / escrowed, leaving about 13M shares free trading. The company owns a portfolio of generic oncology drugs from which it generates over $300K of quarterly revenue. $1M in cash on hand. Based on last financials, they are $83K away from generating positive cash flow and recent developments suggest they will get there sooner rather than later: -- Received grant to develop a rapid COVID-19 saliva based test in partnership with the University of Manitoba -- Received authorization from several EU countries to expand sales of their generic oncology drugs -- Expecting FDA authorization in Q4 2020 At below $10M mkt cap and in the absence of any cheap paper overhang, I feel that this is a tremendous opportunity. Compare it to something like THRM.V which is developing a similar saliva-based COVID-19 test, has next to nothing in revenues, a ton of cheap paper, 3x the float and 3x the market cap, and you realize that current valuation makes no sense. Chart suggests the stock is reversing from short term downtrend after finding bottom at .15. A doji, followed by green candle on increased volume and EMA 20 crossing above EMA 50 providing additional support at .16. Today was a pullback on lower volume that resulted in a higher low. I used it as an opportunity to pad my position. Next catalysts that could propel sp to significantly higher levels are updates on the oncology drug sales in Europe, rapid COVID-19 test development progress and FDA approval of oncology drugs for sale/marketing in the US.
TSXV:WAVELong
by agstockpicks
Vanda Pharmaceuticals! Earnings 40% Trade!!FA: Earings release- the last earnings where the estimate was higher than 0.05 per share it led to the stock rallying by 40%- unless, the earings surprise is a negative one; we can expect a rally from Vanda Pharmaceuticals. TA: Currently been trading in a limited channel- lack of momentum could lead to a dump if earnings estimate is negative or perhaps mean no rally even if the earnings estimate is positive. Watch out for the resistance, it is unlikely to take it out in these market conditions. -Megalodon Whales (Rahim) Enjoyed Charting this for you all,Please SHARE/LIKE/COMMENT and you are welcome to give your feedback or post your own charts below :) NASDAQ:VNDA FWB:VM4
NASDAQ:VNDALong
by BoSukas
2